High‐throughput screening for glutathione conjugates using stable‐isotope labeling and negative electrospray ionization precursor‐ion mass spectrometry
- 10 February 2012
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 26 (6) , 659-669
Abstract
RATIONALE: It has been proposed that the increase in the instances of idiosyncratic adverse drug reactions (IADRs) and black box warnings may be attributed to the occurrence of reactive metabolites. Consequently, a high‐throughput screen for reactive metabolites formed from liver microsome extracts with added glutathione (GSH) was developed for use in the early stages of drug discovery. METHODS: To enhance sensitivity and specificity, as well as accelerate data processing, a mixture of a stable‐isotope probe consisting of natural GSH (light GSH) and stable‐isotope‐labeled [ 15 N, 13 C 2 ] GSH (heavy GSH) at a ratio of 1:1 was used. Any metabolite that reacted with the GSH results in the formation of light and heavy GSH conjugates with a 3 Da difference. Employing a precursor‐ion scan using negative ion electrospray ionization (ESI) corresponding to the expected fragments, signals with the appropriate ratio in the precursor ion scan are then further examined. RESULTS: The new method greatly simplifies data collection by assuming molecules containing GSH will fragment to form specific ions. As such, this approach accelerates data processing (and collection) at the risk of missing compounds that do not fragment as expected. The assay was validated with 33 diverse drugs known to form GSH conjugates, 5 drugs known to not form GSH adducts and over 100 samples containing components of the normal in vitro matrix. In all cases data collected matched the expected result. CONCLUSIONS: The observed sensitivity, specificity, and fast data processing make this assay an excellent fit for high‐throughput screening of reactive metabolites in the early stages of drug discovery. This method is not intended to eliminate compounds or terminate their development. Instead, it is to bring forward molecules with one less liability and thus a greater probability of ultimate success. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- Unbiased High-Throughput Screening of Reactive Metabolites on the Linear Ion Trap Mass Spectrometer Using Polarity Switch and Mass Tag Triggered Data-Dependent AcquisitionAnalytical Chemistry, 2008
- Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed DrugDrug Metabolism and Disposition, 2008
- An algorithm for thorough background subtraction from high‐resolution LC/MS data: application for detection of glutathione‐trapped reactive metabolitesJournal of Mass Spectrometry, 2008
- Detection and Structural Characterization of Glutathione-Trapped Reactive Metabolites Using Liquid Chromatography−High-Resolution Mass Spectrometry and Mass Defect FilteringAnalytical Chemistry, 2007
- The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidatesNature Reviews Drug Discovery, 2007
- SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTINGDrug Metabolism and Disposition, 2005
- Elucidating mechanisms of drug-induced toxicityNature Reviews Drug Discovery, 2005
- Stable-Isotope Trapping and High-Throughput Screenings of Reactive Metabolites Using the Isotope MS SignatureAnalytical Chemistry, 2004
- Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and DevelopmentChemical Research in Toxicology, 2003
- Trapping of metabolically generated electrophilic species with cyanide ion: metabolism of 1-benzylpyrrolidineJournal of Medicinal Chemistry, 1980